Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...